Objective To assess whether children at risk for celiac disease should be screened systematically by comparing their baseline and follow-up characteristics to patients detected because of clinical suspicion.
C eliac disease has become a major public health issue with an estimated prevalence of 1%-3% in many Western and Asian countries. [1] [2] [3] However, because of the variable gastrointestinal and extra-intestinal symptoms involved, the majority of affected children remain unrecognized. 1, 2 Because screening for the disease is available by antibody tests, it has been suggested that diagnostic rates can be increased through screening either known at-risk groups [4] [5] [6] or the entire population. 7 However, although celiac disease fulfils several World Health Organization criteria for population screening, the benefits of this approach remain controversial. 8, 9 In particular, it remains unclear how well mildly symptomatic or asymptomatic screen-detected patients will adhere to a demanding and socially restrictive gluten-free diet. 6, [10] [11] [12] [13] [14] [15] [16] [17] Although untreated celiac disease predisposes to severe complications with increased use of healthcare services in symptomatic patients, 9, 18, 19 it is not known whether this applies to screen-detected individuals, who may possible have less severe histologic damage 20 and, consequently, better long-term outcome. Then again, complications such as poor growth, dental enamel defects, and low bone mass have been observed even in otherwise asymptomatic children with celiac disease, and these maladies may remain permanent if left untreated. [21] [22] [23] To evaluate the potential benefits and detriments of celiac disease screening, we compared clinical, serologic, and histologic features and follow-up results between children detected during the course of risk-group screening and those identified on clinical suspicion. 
Methods
The study was conducted at the Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, and at the Department of Pediatrics, Tampere University Hospital. Patient data were collected from our research database, which contains medical information on children diagnosed with celiac disease from the late 1960s to the present. Lacking or incomplete patient information has been supplemented with personal or telephone interviews by an experienced physician or study nurse. From the year 2012 onward, most of the database patients have participated in a prospective study enrolment. To increase the integrity of the results, only children diagnosed from the year 2000 onward were included. Exclusion criteria were age ≥18 years, unclear diagnosis of celiac disease, and lack of data regarding the initial clinical presentation. Altogether, 504 children with celiac disease proven by biopsy comprised the final study cohort.
The following celiac disease-related information was collected on each child at the time of the diagnosis: clinical characteristics, severity of histologic damage, celiac disease serology, a variety of other laboratory variables, and presence of celiac disease in the family. Follow-up data regarding adherence and clinical and serologic response to the gluten-free diet were recorded. The results were compared between children detected by screening and those found on the basis of clinical suspicion. For the corresponding subgroup analysis, screendetected children were further divided into asymptomatic and symptomatic patients.
The Pediatric Clinic of Tampere University Hospital and the Ethics Committee of the Pirkanmaa Hospital District, Tampere, Finland, approved the study. Written informed consent was obtained from all subjects and/or their parents participating in the personal interviews or prospective study enrollment.
Screen-detected patients included at-risk children such as those with celiac disease in relatives (first degree or more distant), type 1 diabetes mellitus (T1DM), or autoimmune thyroidal disease as a comorbidity. Some patients were screened for celiac disease because of attendance in a follow-up study attributable to increased genetic risk for T1DM. Clinically detected children were diagnosed on the basis of gastrointestinal or extra-intestinal symptoms or findings, including diarrhea, abdominal pain, constipation, arthralgia, dermatitis herpetiformis, anemia, and poor growth. Severity of symptoms was classified as no symptoms; mild symptoms (occasionally disturbing minor symptoms); moderate symptoms (more frequent and distracting symptoms); and severe symptoms (distracting symptoms causing recurrent nighttime awakenings, school absence, etc). Anemia and poor growth were considered as findings or complications of celiac disease and were, thus, not included in the classification of symptoms. Height and weight at the diagnosis were noted and expressed in age-and sex-dependent SD units. Poor growth was defined based on abnormalities in expected height and growth velocity as described elsewhere. 23, 24 Body mass index was calculated as weight/height 2 (kg/m 2 ).
Small-Bowel Mucosal Damage and Laboratory Variables
At least 4 distal duodenal mucosal samples were taken during gastrointestinal endoscopy in all children with suspected celiac disease. From 2012 onward, samples were also obtained from the duodenal bulb. 25 The severity of mucosal damage was assessed from several well-orientated biopsy sections 26 and further categorized as mild (Marsh IIIa) , moderate (Marsh IIIb), or total villous atrophy (Marsh IIIc).
Transglutaminase 2 antibodies (TG2ab) were measured by either automatized automated enzyme fluoroimmunoassay assay (Phadia AB, Uppsala, Sweden), or before 2011 by conventional enzyme-linked immunosorbent assay (Phadia). Values 7 U/L or higher for TG2ab are considered positive; 120 U/L is the highest reported value. Serum endomysial antibodies (EmAs) were measured by indirect immunofluorescence as previously described. 20, 27 A dilution of 1: ≥5 for EmA was considered positive and further diluted up to 1:4000 or until negative.
Results of the following laboratory tests were collected on each child when available: hemoglobin (g/L), erythrocyte mean corpuscular volume (reference value [Rf] 73-95 fL), plasma albumin (Rf 36-48 g/L), plasma transferrin receptor (TfR) (ageand sex-matched Rf), 28 plasma ferritin (Rf >20 mg/L), plasma alanine aminotransferase (Rf ≤30 U/L), 29 and plasma thyroidstimulating hormone (TSH) (Rf 0.27-4.2 mU/L). Anemia was defined as a hemoglobin value below the age-and sex-matched reference. 30 For consistency, only laboratory values taken at the time of diagnostic evaluations were accepted for the baseline comparisons. Values other than hemoglobin were systematically obtained only during the latter part of the study period.
Follow-Up Investigations
All children initiated a gluten-free diet shortly after the diagnosis under the supervision of a qualified dietitian. Adherence to the diet was assessed during each follow-up visit based on self-reported gluten avoidance and results of serology, and categorized into strict diet, occasional lapses, and no diet. Clinical and serologic response to the dietary treatment was also evaluated and classified as (1) good response (disappearance of symptoms and normalized or markedly decreased celiac antibody levels); or (2) no response (persistent symptoms and/ or antibody positivity). Routine follow-up visits took place approximately 3-6 and 10-12 months after the celiac disease diagnosis. Further, 120 of the children were interviewed after a median of 4 years from the diagnosis. Results of follow-up serology were analyzed by comparing the baseline TG2ab values with those measured after a median of 13 (range 6-24) months on a gluten-free diet.
Statistical Analyses
Categorized variables are reported as percentage distributions and numeric variables as medians with quartiles. Fisher exact test or c 2 test was used to compare categorized variables and Mann-Whitney U test with numeric variables. Binary logistic regression was used to adjust age differences between the groups. A P value of <.05 was considered significant.
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Analyses were performed with SPSS v 22 (IBM Corporation, Armonk, New York).
Results
Altogether, 145 (28.8%) children were detected by screening and 359 (71.2%) on a clinical basis ( Table I) . The main presentation was gastrointestinal in 68.0% and extra-intestinal in 32.0% of the patients detected because of symptoms. There were no differences between screen-and clinically detected children in age or sex, but celiac disease in first-degree relatives and concomitant T1DM were more common among the screen-detected children ( Table I) ; these were also the primary reasons for screening. More clinically detected patients had anemia and poor growth, but these disorders were also seen in a substantial proportion of those identified by screening (Table I) .
Furthermore, 51.8% of the screen-detected children reported symptoms at diagnosis, usually less severe than in patients diagnosed clinically (Figure 1 , A-B; available at www.jpeds.com). Diarrhea or loose stools were more common among clinically detected patients, but otherwise the groups did not differ in the distribution of symptoms (Table II; available at www.jpeds.com). There were no significant differences between the study groups in anthropometric measurements (Table III) or severity of histologic damage (Figure 1,  C) . In 3 screen-detected and in 10 clinically detected children, the celiac disease diagnosis was based on lesions in the duodenal bulb only (P = 1.000). The median blood hemoglobin and serum albumin were slightly lower among clinically detected subjects (Table III) , but except for anemia, the prevalence of abnormal laboratory values did not differ between the groups (clinically vs screen-detected): low albumin 23.0% vs 10.5%, P = .343; erythrocyte mean corpuscular volume 10.6% vs 13.4%, P = .515; and ferritin 20.5% vs 20.0% P = .958; and increased plasma transferrin receptor 31.3% vs 22.2%, P = .451; plasma alanine aminotransferase 15.6% vs 16.0%, P = 1.000; and plasma thyroid-stimulating hormone 14.2% vs 7.3%, P = .251, respectively.
Adherence to a gluten-free diet was better among the screendetected children (Figure 1, D) . However, there was no significant association between the presence of strict adherence and celiac disease in the family (celiac disease 81.3% vs no disease 90.4%, P = .060) or concomitant T1DM in the child (T1DM 85.8% vs no T1DM 84.6%, P = .835). The clinical and serologic response were equally good in both groups (97.5% vs 96.2%, P = .766). Similarly, while on diet serum TG2abs decreased in all but 2 screen-detected and in all clinically detected patients (Figure 2) . On later follow-up, the antibodies declined in the 2 cases with no initial response (data not shown). The median time on a gluten-free diet before the follow-up TG2ab measurement was comparable between the screen-detected and clinically detected children (12.0 vs 11.0 months, P = .090).
Among the screen-detected patients, symptomatic children were significantly younger and had higher EmA and lower median hemoglobin compared with those who were asymptomatic upon crude analysis, but the differences were no longer significant when adjusted for age (Table IV) . There were no differences between the subgroups in sex, growth variables or presence of anemia, concomitant T1DM and celiac disease in relatives (Table IV) , or prevalence of abnormal laboratory values (data not shown). Further, the screen-detected groups were comparable in severity of histologic damage and dietary adherence (Figure 3 ; available at www.jpeds.com).
There was no association between EmA or TG2ab levels and the severity of villous atrophy in screen-detected patients 
Discussion
The present study demonstrated that even screen-detected children often have unrecognized clinical symptoms and signs of celiac disease before diagnosis. Furthermore, these patients are comparable with those found on clinical basis with respect to histologic and serologic markers of disease severity and have better adherence and response to the gluten-free diet. Our findings support active screening of celiac disease among at-risk children. Conversely, the benefits of screening the general population remain obscure.
Over one-half of the screen-detected children reported glutenresponsive symptoms, which had neither led to a doctor visit nor been recognized as celiac disease in clinical practice. In line with this, recent studies conducted among screened children and adults have shown 34%-84% of such patients suffer from unrecognized symptoms at the time of the celiac disease diagnosis. 11, 15, 31, 32 These findings demonstrate that symptombased case finding may not even detect a number of children with classical gastrointestinal manifestations, let alone those who present with atypical or subtle symptoms. What is more, most of the above mentioned pediatric screening studies have been conducted in Finland and other Nordic countries, where the disease is fairly well-known among pediatricians and primary care physicians, 15, 32 and in other countries, the situation might 
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Volume 183 be even poorer. For example, in the US only 17% of all patients with celiac disease were aware of their disorder before population screening, 33 and underdiagnosis has also been observed in New Zealand and Australia. 34 Besides unrecognized symptoms, many of the screendetected children suffered from poor growth and anemia, which were not recognized as a sign of celiac disease before the screening. There has been debate as to whether the risk of longterm complications is similar among screen-and clinically detected patients, 9, 18 but data actually comparing these 2 groups are limited. Previously Korponay-Szabó et al 35 reported a prevalence of 22% for anemia and 31% for poor growth in a population-based cohort of screen-detected schoolchildren in Hungary. We have also shown these features to be present in otherwise asymptomatic patients, 23, 36 and there is some evidence that the introduction of a gluten-free diet can improve growth and hemoglobin values in screen-detected children. 37 Other possible complications, which have been observed regardless of the clinical presentation of celiac disease, are low bone mineral density, dental enamel defects, and elevated transaminases. 21, 22, 29, 38 In support of the presence of advanced disease and risk of complications, the screen-detected children had levels of celiac disease autoantibodies and severity of villous atrophy similar to those detected on a clinical basis. It is possible that, despite equal severity of histologic injury, the clinically detected group had longer length of small intestinal injury, which may explain their apparent gastrointestinal symptoms. 39 However, current evidence in adults does not support this hypothesis. 40 Earlier studies have yielded inconsistent results on the correlation between clinical picture and histologic findings in celiac disease. 20, [41] [42] [43] Apart from differences in study designs, these discrepancies might be at least partly explained by differences in clinical presentation of the disease between countries. Studies from many developed countries have reported that the severity of celiac disease is becoming milder even in the subgroup of patients suffering from classic gastrointestinal symptoms. 44, 45 This may contribute to the increasing similarity between clinically and screen-detected children. Nevertheless, in favor of early diagnosis and treatment, more than one-half of the children in both groups already had either moderate or total villous atrophy at diagnosis.
To justify screening, we consider it of prime importance that compliance with the gluten-free diet is comparable among screen-and symptom-detected children. In support of excellent dietary adherence, the study groups showed equal clinical and serologic response to the diet. Although not all had complete normalization of antibodies during follow-up, a similar slow response in some patients with celiac disease has been noted elsewhere. 12, 37 The present study confirmed the results of our previous survey-based study, in which the diagnostic approach had no effect on dietary adherence, 15 and similar observations have recently been reported from The Netherlands and Sweden. 12, 14 In contrast, in an earlier Italian study, only 23% of screen-detected adolescents had satisfactory adherence to a gluten-free diet 5 years after the celiac disease diagnosis. 10 However, these patients were found by population-based mass screening. Additional explanations for variable adherence might be differences in the availability and cost of gluten-free products in many countries and in awareness of celiac disease, for example, in restaurants. 46 In Finland and some other countries, governments financially support every child with confirmed celiac disease, 47 although this was also the case in the above-mentioned Italian study showing poor adherence. 10 Other factors likely affecting dietary adherence include the intensity and organization of follow-up, the availability of a dietician, the presence of comorbidities, and celiac disease in other family members. 13, 16, 48 Of note, we found no association between the adherence and presence of concomitant T1DM in the child or celiac disease in the family. Regardless, our results demonstrate that excellent adherence to the gluten-free diet is attainable in screen-detected patients with celiac disease diagnosed and followed in a well-organized clinical practice.
Even if the benefits of the gluten-free diet in the present and some earlier studies favor screening and active treatment of celiac disease, 6, 15, 17, 31 there is reason for caution. Besides the social restrictions and economic burden, 6, 11, 49 it is possible that the diet predisposes some patients to suboptimal intake of vitamins and trace elements and to obesity. 50, 51 Furthermore, despite the promising short-term results, there is a risk that dietary adherence will decline in adolescence and adulthood, when follow-up usually becomes less frequent and responsibility for daily treatment shifts from the parents to the patients themselves. This issue has been scantily studied, but Van Koppen et al 14 reported good adherence and improved health in a majority of screen-detected children 10 years after diagnosis. In contrast, in an earlier study by O'Leary et al 52 only 50% of the patients with celiac disease diagnosed in childhood remained on a strict gluten-free diet after a median of 28 years of followup. In adults, dietary lapses have been a problem particularly in asymptomatic patients, 11 whereas this was not the case in the present study. More studies evaluating dietary adherence and the benefits of a gluten-free diet in the long term in screendetected children are required.
The main strengths of the present study were the large cohort of patients with celiac disease diagnosed on uniform nationwide criteria, and the wide array of serologic and histologic variables assessed. In addition, follow-up data regarding adherence and clinical and serologic response to the glutenfree diet were documented in the majority of the children. The main limitations include the retrospective design, lack of systematic collection of laboratory variables other than serology during the whole study period and the lack of structured questionnaire for collection of symptoms, and dietary adherence. Further, the median follow-up time in the study was too short to estimate long-term dietary adherence and the effects of an early initiated gluten-free diet on the possible complications and comorbidities of celiac disease.
In conclusion, the high percentage of unrecognized clinical symptoms and excellent response and adherence to the gluten-free diet support active screening of celiac disease in at-risk children. An alternative option might be low-threshold case finding among at-risk children, but it is important to realize that even apparently asymptomatic patients may have welladvanced serologic and histologic disease and a subsequent risk of long-term complications. ■ 
